What is the projected market valuation of the STD diagnostic market by 2035?

The STD diagnostic market is projected to reach a valuation of 10.5 USD Billion by 2035. Read More

What was the market valuation of the STD diagnostic market in 2024?

In 2024, the STD diagnostic market was valued at 5.504 USD Billion. Read More

What is the expected CAGR for the STD diagnostic market during the forecast period 2025 - 2035?

The expected CAGR for the STD diagnostic market during the forecast period 2025 - 2035 is 6.05%. Read More

Which test type segment is projected to have the highest growth in the STD diagnostic market?

The Nucleic Acid Amplification Tests segment is projected to grow from 1.5 USD Billion in 2024 to 3.0 USD Billion by 2035. Read More

How does the market for HIV diagnostics compare to other diseases in 2024?

In 2024, the market for HIV diagnostics was valued at 2.0 USD Billion, making it the largest segment among other diseases. Read More

What are the key players in the STD diagnostic market?

Key players in the STD diagnostic market include Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific, among others. Read More

Which end-user segment is expected to see the most significant growth by 2035?

The At-Home Testing segment is expected to grow from 1.804 USD Billion in 2024 to 3.1 USD Billion by 2035. Read More

What is the projected growth for the Serology Tests segment from 2024 to 2035?

The Serology Tests segment is projected to increase from 1.2 USD Billion in 2024 to 2.4 USD Billion by 2035. Read More

How does the market for Gonorrhea diagnostics compare to that of Syphilis in 2024?

In 2024, the Gonorrhea diagnostics market was valued at 0.9 USD Billion, while the Syphilis diagnostics market was valued at 0.5 USD Billion. Read More

What sample type is expected to dominate the STD diagnostic market by 2035?

Blood Samples are expected to dominate the STD diagnostic market, growing from 1.5 USD Billion in 2024 to 3.0 USD Billion by 2035. Read More

Sexually Transmitted Diseases Diagnostic Market

ID: MRFR/HC/41834-HCR

128 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Sexually Transmitted Diseases (STD) Diagnostics Market Research Report: Size, Share, Trend Analysis By Test Type (Nucleic Acid Amplification Tests, Serology Tests, Rapid Diagnostic Tests, Polymerase Chain Reaction Tests), By Disease Type (Chlamydia, Gonorrhea, Syphilis, HIV, Herpes Simplex Virus), By End Users (Hospitals, Clinics, Laboratories, At-Home Testing), By Sample Type (Blood Samples, Urine Samples, Swab Samples, Tissue Samples) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Sexually Transmitted Diseases Diagnostic Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.05%

2024 Market Size$ 5.5 Billion

2025 Market Size$ 5.84 Billion

2035 Market Size$ 10.5 Billion

Key Players

Companies such as  Abbott Laboratories

Roche Diagnostics

Thermo Fisher Scientific

Siemens Healthineers

Hologic

Inc.

Trends

Technological Advancements in Diagnostics
Integration of Digital Health Solutions
Increased Awareness and Education

Opportunities

Rising Incidence of STDs
Rising Healthcare Expenditure
Government Initiatives and Funding

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Test Type (USD Billion) | |
  1. 4.1.1 Nucleic Acid Amplification Tests | |
  2. 4.1.2 Serology Tests | |
  3. 4.1.3 Rapid Diagnostic Tests | |
  4. 4.1.4 Polymerase Chain Reaction Tests |
2. 4.2 Healthcare, BY Disease Type (USD Billion) | |
  1. 4.2.1 Chlamydia | |
  2. 4.2.2 Gonorrhea | |
  3. 4.2.3 Syphilis | |
  4. 4.2.4 HIV | |
  5. 4.2.5 Herpes Simplex Virus |
3. 4.3 Healthcare, BY End User (USD Billion) | |
  1. 4.3.1 Hospitals | |
  2. 4.3.2 Clinics | |
  3. 4.3.3 Laboratories | |
  4. 4.3.4 At-Home Testing |
4. 4.4 Healthcare, BY Sample Type (USD Billion) | |
  1. 4.4.1 Blood Samples | |
  2. 4.4.2 Urine Samples | |
  3. 4.4.3 Swab Samples | |
  4. 4.4.4 Tissue Samples |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Abbott Laboratories (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Roche Diagnostics (CH) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Thermo Fisher Scientific (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Siemens Healthineers (DE) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Hologic, Inc. (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 BD (Becton, Dickinson and Company) (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Cepheid (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 bioMérieux (FR) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Ortho Clinical Diagnostics (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TEST TYPE |
7. 6.4 US MARKET ANALYSIS BY DISEASE TYPE |
8. 6.5 US MARKET ANALYSIS BY END USER |
9. 6.6 US MARKET ANALYSIS BY SAMPLE TYPE |
10. 6.7 CANADA MARKET ANALYSIS BY TEST TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY DISEASE TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY END USER |
13. 6.10 CANADA MARKET ANALYSIS BY SAMPLE TYPE |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TEST TYPE |
16. 6.13 GERMANY MARKET ANALYSIS BY DISEASE TYPE |
17. 6.14 GERMANY MARKET ANALYSIS BY END USER |
18. 6.15 GERMANY MARKET ANALYSIS BY SAMPLE TYPE |
19. 6.16 UK MARKET ANALYSIS BY TEST TYPE |
20. 6.17 UK MARKET ANALYSIS BY DISEASE TYPE |
21. 6.18 UK MARKET ANALYSIS BY END USER |
22. 6.19 UK MARKET ANALYSIS BY SAMPLE TYPE |
23. 6.20 FRANCE MARKET ANALYSIS BY TEST TYPE |
24. 6.21 FRANCE MARKET ANALYSIS BY DISEASE TYPE |
25. 6.22 FRANCE MARKET ANALYSIS BY END USER |
26. 6.23 FRANCE MARKET ANALYSIS BY SAMPLE TYPE |
27. 6.24 RUSSIA MARKET ANALYSIS BY TEST TYPE |
28. 6.25 RUSSIA MARKET ANALYSIS BY DISEASE TYPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY END USER |
30. 6.27 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE |
31. 6.28 ITALY MARKET ANALYSIS BY TEST TYPE |
32. 6.29 ITALY MARKET ANALYSIS BY DISEASE TYPE |
33. 6.30 ITALY MARKET ANALYSIS BY END USER |
34. 6.31 ITALY MARKET ANALYSIS BY SAMPLE TYPE |
35. 6.32 SPAIN MARKET ANALYSIS BY TEST TYPE |
36. 6.33 SPAIN MARKET ANALYSIS BY DISEASE TYPE |
37. 6.34 SPAIN MARKET ANALYSIS BY END USER |
38. 6.35 SPAIN MARKET ANALYSIS BY SAMPLE TYPE |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USER |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TEST TYPE |
45. 6.42 CHINA MARKET ANALYSIS BY DISEASE TYPE |
46. 6.43 CHINA MARKET ANALYSIS BY END USER |
47. 6.44 CHINA MARKET ANALYSIS BY SAMPLE TYPE |
48. 6.45 INDIA MARKET ANALYSIS BY TEST TYPE |
49. 6.46 INDIA MARKET ANALYSIS BY DISEASE TYPE |
50. 6.47 INDIA MARKET ANALYSIS BY END USER |
51. 6.48 INDIA MARKET ANALYSIS BY SAMPLE TYPE |
52. 6.49 JAPAN MARKET ANALYSIS BY TEST TYPE |
53. 6.50 JAPAN MARKET ANALYSIS BY DISEASE TYPE |
54. 6.51 JAPAN MARKET ANALYSIS BY END USER |
55. 6.52 JAPAN MARKET ANALYSIS BY SAMPLE TYPE |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USER |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TEST TYPE |
61. 6.58 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY END USER |
63. 6.60 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE |
64. 6.61 THAILAND MARKET ANALYSIS BY TEST TYPE |
65. 6.62 THAILAND MARKET ANALYSIS BY DISEASE TYPE |
66. 6.63 THAILAND MARKET ANALYSIS BY END USER |
67. 6.64 THAILAND MARKET ANALYSIS BY SAMPLE TYPE |
68. 6.65 INDONESIA MARKET ANALYSIS BY TEST TYPE |
69. 6.66 INDONESIA MARKET ANALYSIS BY DISEASE TYPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY END USER |
71. 6.68 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TEST TYPE |
73. 6.70 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY END USER |
75. 6.72 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TEST TYPE |
78. 6.75 BRAZIL MARKET ANALYSIS BY DISEASE TYPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY END USER |
80. 6.77 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE |
81. 6.78 MEXICO MARKET ANALYSIS BY TEST TYPE |
82. 6.79 MEXICO MARKET ANALYSIS BY DISEASE TYPE |
83. 6.80 MEXICO MARKET ANALYSIS BY END USER |
84. 6.81 MEXICO MARKET ANALYSIS BY SAMPLE TYPE |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TEST TYPE |
86. 6.83 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY END USER |
88. 6.85 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USER |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USER |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TEST TYPE |
103. 6.100 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY END USER |
105. 6.102 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY END USER, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY DISEASE TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY SAMPLE TYPE, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Sexually Transmitted Diseases Diagnostic Market Segmentation

Sexually Transmitted Diseases Diagnostic Market By Test Type (USD Billion, 2025-2035)

Nucleic Acid Amplification Tests
Serology Tests
Rapid Diagnostic Tests
Polymerase Chain Reaction Tests

Sexually Transmitted Diseases Diagnostic Market By Disease Type (USD Billion, 2025-2035)

Chlamydia
Gonorrhea
Syphilis
HIV
Herpes Simplex Virus

Sexually Transmitted Diseases Diagnostic Market By End User (USD Billion, 2025-2035)

Hospitals
Clinics
Laboratories
At-Home Testing

Sexually Transmitted Diseases Diagnostic Market By Sample Type (USD Billion, 2025-2035)

Blood Samples
Urine Samples
Swab Samples
Tissue Samples

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035